Quantcast

Latest Biogen Idec Stories

2014-08-12 08:29:26

Array planning for potential return of MEK inhibitor BOULDER, Colo., Aug. 12, 2014 /PRNewswire/ -- Array BioPharma Inc.

2014-08-07 12:28:48

Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.

2014-08-06 16:29:29

- 'Clinical Map Initiative' On Track; Human Proof of Concept Results for RG-101 and Nomination of Third Clinical Candidate Expected by YE 2014 - LA JOLLA, Calif., Aug.

2014-08-01 08:25:54

-- ENDEAR Trial To Enroll 110 SMA Infants at Sites Globally CARLSBAD, Calif., Aug. 1, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.

2014-07-26 23:01:46

MarketOptimizer.org adds “Multiple Sclerosis Global Clinical Trials Review, H2, 2014” to its store.

2014-07-23 16:27:46

RICHMOND, Calif., July 23, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.

2014-07-22 12:27:43

Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass.,

2014-07-16 16:23:59

RICHMOND, Calif., July 16, 2014 /PRNewswire/ -- Sangamo BioSciences, Inc.

2014-07-07 08:27:16

Editor Note: For more information about this release, please scroll to bottom. LONDON, July 7, 2014 /PRNewswire/ -- On Thursday, July 03, 2014, the NASDAQ Composite


Word of the Day
gubbings
  • The parings of haberdine; also, any kind of fragments.
The word 'gubbings' is a variant of the word 'gobbon', meaning 'a portion, gobbet.'